HEPAR Primary showed an acceptable toxicity profile and demonstrated an objective response rate of 54 % (14/26 patients) after 3 months, according to mRECIST evaluation of target liver lesions.
“We are very excited about the safety and efficacy results of our HCC study, in which we have been using QuiremScoutTM for the work-up and QuiremSpheresTM for the SIRT treatment. At the start of our study, we did not have the opportunity to use the pre-treatment planning functionalities of the Q-SuiteTM imaging software (launched in September 2020),” said author, Prof. Dr. M. Lam. “Looking towards the future, I strongly believe that we can achieve even better clinical outcomes by truly individualizing the treatment of each patient using the entire Holmium Platform. Therefore, we are currently recruiting patients in a new multi-centre iHEPAR study to further demonstrate the importance of individualizing SIRT in HCC using the full Holmium Platform.”
The Holmium Platform consists of three integrated products, QuiremScoutTM holmium-166 microspheres, QuiremSpheresTM holmium-166 microspheres and Q-SuiteTM imaging software, that allow HCPs to select patients with confidence, deliver treatment with precision and plan and verify with accuracy.
“We are delighted with the results of the HEPAR Primary study that demonstrates the benefits of Holmium Selective Internal Radiation Therapy in the treatment of primary liver cancer. This study is an additional demonstration of the value of our Holmium platform and the synergies that are brought by using QuiremScoutTM and QuiremSpheresTM together. We are confident this will continue supporting the adoption of the Holmium Platform“, said Laurent Domas Global Vice President of Strategy & Therapy development, Interventional Oncology Terumo.
Commenting on the results of the HCC study, Ghada Farah, Senior Vice President of Terumo Interventional Systems EMEA added: “These exciting results are another very important milestone for the Holmium Platform. We at Terumo believe it is vital to deliver truly individualized SIRT treatment to the right patient and with The Holmium Platform, we can do exactly that.”
For more information related to the Holmium Platform, please visit our QuiremSpheresTM product page.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
About Terumo Europe
Terumo Europe N.V. is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets, and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Medical Products, Cardiovascular Products and Diabetes Management. Terumo Europe EMEA headquarters and production facilities are located in Leuven (Belgium), production facility in Knowsley (UK), European Distribution Center in Genk (Belgium) and sales offices across EMEA.
